IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Sold by Ensign Peak Advisors Inc

Ensign Peak Advisors Inc decreased its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 14.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 34,006 shares of the company’s stock after selling 5,609 shares during the period. Ensign Peak Advisors Inc’s holdings in IDEXX Laboratories were worth $16,568,000 at the end of the most recent quarter.

Other institutional investors have also modified their holdings of the company. Capital Research Global Investors bought a new stake in shares of IDEXX Laboratories during the 4th quarter worth $135,910,000. American Century Companies Inc. grew its stake in IDEXX Laboratories by 46.0% in the 2nd quarter. American Century Companies Inc. now owns 562,764 shares of the company’s stock valued at $274,179,000 after buying an additional 177,226 shares during the last quarter. TD Asset Management Inc increased its position in IDEXX Laboratories by 178.8% in the 4th quarter. TD Asset Management Inc now owns 260,008 shares of the company’s stock worth $144,317,000 after buying an additional 166,751 shares during the period. Point72 Asset Management L.P. acquired a new position in IDEXX Laboratories during the 4th quarter valued at $78,001,000. Finally, Jupiter Asset Management Ltd. bought a new position in shares of IDEXX Laboratories during the 1st quarter worth about $55,425,000. Institutional investors and hedge funds own 87.84% of the company’s stock.

IDEXX Laboratories Price Performance

Shares of IDXX opened at $507.66 on Tuesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.03 and a current ratio of 1.37. IDEXX Laboratories, Inc. has a 52-week low of $372.50 and a 52-week high of $583.39. The stock has a 50 day simple moving average of $484.35 and a 200 day simple moving average of $498.35. The firm has a market capitalization of $41.93 billion, a PE ratio of 49.14, a P/E/G ratio of 4.17 and a beta of 1.33.

IDEXX Laboratories (NASDAQ:IDXX) last posted its quarterly earnings data on Tuesday, August 6th. The company reported $2.44 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $2.88 by ($0.44). IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The firm had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.01 billion. During the same quarter in the previous year, the business posted $2.67 earnings per share. The firm’s quarterly revenue was up 6.4% compared to the same quarter last year. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 10.45 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on IDXX shares. Piper Sandler cut their price objective on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating for the company in a report on Wednesday, August 14th. Stifel Nicolaus decreased their price target on shares of IDEXX Laboratories from $520.00 to $510.00 and set a “hold” rating on the stock in a research note on Monday, June 24th. StockNews.com lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. Finally, BTIG Research assumed coverage on shares of IDEXX Laboratories in a research note on Thursday, July 25th. They issued a “buy” rating and a $580.00 price objective on the stock. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $582.25.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.